TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

Company Overview

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.03 to $0.05
• 50-Day Range: $0.02 to $0.08
• 52-Week Range: $0.00 to $14.75
• Volume: 23,800 shs
• Average Volume: 120,908 shs
• Market Capitalization: $109,802.00
• P/E Ratio: 0.01
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Hold

TRACON Pharmaceuticals Stock Analysis - MarketRank™

TRACON Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

TRACON Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

TRACON Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TRACON Pharmaceuticals is 0.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.17.

Price to Earnings Ratio vs. Sector

The P/E ratio of TRACON Pharmaceuticals is 0.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.07.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TCON.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TRACON Pharmaceuticals does not currently pay a dividend.

Dividend Growth

TRACON Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for TCON.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for TCON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 11.61% of the stock of TRACON Pharmaceuticals is held by institutions.

TCON Stock Analysis - Frequently Asked Questions

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) posted its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company had revenue of $0.10 million for the quarter.

When did TRACON Pharmaceuticals' stock split?

TRACON Pharmaceuticals shares reverse split before market open on Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TRACON Pharmaceuticals IPO?

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/14/2024
• Today: 1/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCON
• CUSIP: N/A
• CIK: 1394319
• Web: www.traconpharma.com
• Phone: (858) 550-0780
• Fax: 858-550-0786
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.00
• High Stock Price Target: $60.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +186,235.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $3.73
• Trailing P/E Ratio: 0.01
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,590,000.00
• Net Margins: N/A
• Pretax Margin: 145.93%
• Return on Equity: -237.65%
• Return on Assets: 57.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.66
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $12.05 million
• Price / Sales: 0.01
• Cash Flow: $1.61 per share
• Price / Cash Flow: 0.02
• Book Value: ($0.37) per share
• Price / Book: -0.09

Miscellaneous

• Outstanding Shares: 3,410,000
• Free Float: 3,228,000
• Market Cap: $109,802.00
• Optionable: No Data
• Beta: 1.37